Breaking News Instant updates and real-time market news.

AAPL

Apple

$130.82 /

++0.85 (++0.66%)

11:04
06/03/15
06/03
11:04
06/03/15
11:04

Music another way Apple adding to non-hardware revenue, says Piper Jaffray

Piper Jaffray analyst Gene Munster noted that reports suggest Apple will launch a new streaming music service next week at its WWDC event, which he believes will benefit the iPhone user experience, but not add in any meaningful way to the company's finances. However, Munster thinks the company's recent trend of rolling out services like this and Apple Pay to layer new revenue streams on top of its hardware are a sign that the company's innovation continues and will be positive for the stock's multiple. Munster keeps an Overweight rating and $162 price target on Apple shares.

AAPL Apple
$130.82 /

++0.85 (++0.66%)

06/02/15 UBS
Apple downside risk in 2016 already factored in, says UBS
06/02/15 Brean Capital
Apple to beat June quarter estimates materially, says Brean Capital
06/01/15 UBS
Most Preferred List changes at UBS
05/28/15 UBS
Apple investors may be underestimating China, says UBS

TODAY'S FREE FLY STORIES

Syndicate
Great Panther Mining re-establishes $25M at-the-market facility » 18:26
10/15/21
10/15
18:26
10/15/21
18:26
GPL

Great Panther Mining

/

+

Great Panther Mining…

Great Panther Mining announces that it has entered into an At-the-Market Offering Agreement of up to $25M dated October 15, with H.C. Wainwright & Co.. This offering replaces the company's prior $25M At-the-Market offering, which expired on August 3.

ShowHide Related Items >><<
GPL Great Panther Mining
/

+

GPL Great Panther Mining
/

+

10/09/21 Cantor Fitzgerald
Great Panther Mining downgraded to Hold from Buy at Cantor Fitzgerald
10/08/21 Alliance Global Partners
Great Panther price target lowered to 70c from $1.20 at Alliance Global
10/29/20 Roth Capital
Great Panther Mining resumed with a Buy at Roth Capital
Hot Stocks
TherapeuticsMD names Mark Glickman as Chief Business Officer » 17:34
10/15/21
10/15
17:34
10/15/21
17:34
TXMD

TherapeuticsMD

/

+

TherapeuticsMD announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TXMD TherapeuticsMD
/

+

TXMD TherapeuticsMD
/

+

08/05/21 Cowen
TherapeuticsMD price target lowered to $5 from $9 at Cowen
01/28/21 H.C. Wainwright
TherapeuticsMD price target lowered to $4 from $5 at H.C. Wainwright
TXMD TherapeuticsMD
/

+

  • 11
    Feb
  • 10
    Nov
Periodicals
Stellantis to turn Windsor plant into one-shift operation, Automotive News says » 17:28
10/15/21
10/15
17:28
10/15/21
17:28
STLA

Stellantis

$19.98 /

+0.145 (+0.73%)

Stellantis intends to…

Stellantis intends to convert its Windsor, Ontario minivan factory into a one-shift operation starting in the spring of 2022, Automotive News Canada's Greg Layson reports. The car marker did not say when one of the two remaining shifts will be cut, but it did blame the ongoing chip shortage and COVID-19 pandemic for the change, the author notes. Reference Link

ShowHide Related Items >><<
STLA Stellantis
$19.98 /

+0.145 (+0.73%)

STLA Stellantis
$19.98 /

+0.145 (+0.73%)

09/07/21 KeyBanc
Jeep micro site on Amazon points to auto sales moving online, says KeyBanc
09/03/21 Deutsche Bank
Stellantis deal 'significant opportunity' for Open Lending, says Deutsche Bank
09/02/21 DA Davidson
DA Davidson says Stellantis opportunity for Open Lending not 'fait accompli'
09/02/21 Raymond James
Raymond James says buy Open Lending aggressively after Stellantis deal
STLA Stellantis
$19.98 /

+0.145 (+0.73%)

STLA Stellantis
$19.98 /

+0.145 (+0.73%)

STLA Stellantis
$19.98 /

+0.145 (+0.73%)

Syndicate
Renovacor files to sell 12.67M shares of common stock for holders  17:15
10/15/21
10/15
17:15
10/15/21
17:15
RCOR

Renovacor

$8.15 /

+0.36 (+4.62%)

 
ShowHide Related Items >><<
RCOR Renovacor
$8.15 /

+0.36 (+4.62%)

RCOR Renovacor
$8.15 /

+0.36 (+4.62%)

10/14/21 Ladenburg
Renovacor initiated with a Buy at Ladenburg
10/14/21 Ladenburg
Renovacor initiated with a Buy at Ladenburg
10/01/21 Chardan
Renovacor initiated with a Buy, $20 target at Chardan
10/01/21 Chardan
Renovacor initiated with a Buy at Chardan
Syndicate
Renovacor files to sell 8.53M shares of common stock  17:15
10/15/21
10/15
17:15
10/15/21
17:15
RCOR

Renovacor

$8.15 /

+0.36 (+4.62%)

 
ShowHide Related Items >><<
RCOR Renovacor
$8.15 /

+0.36 (+4.62%)

RCOR Renovacor
$8.15 /

+0.36 (+4.62%)

10/14/21 Ladenburg
Renovacor initiated with a Buy at Ladenburg
10/14/21 Ladenburg
Renovacor initiated with a Buy at Ladenburg
10/01/21 Chardan
Renovacor initiated with a Buy, $20 target at Chardan
10/01/21 Chardan
Renovacor initiated with a Buy at Chardan
Hot Stocks
Revance gets CRL from FDA, says it is unable to approve DaxibotulinumtoxinA BLA » 17:13
10/15/21
10/15
17:13
10/15/21
17:13
RVNC

Revance

$22.72 /

+0.24 (+1.07%)

Revance announced that…

Revance announced that the FDA has issued a complete response letter, or CRL, regarding the biologics license application, or BLA, for DaxibotulinumtoxinA for injection, for the treatment of moderate to severe glabellar lines. In a communication received on October 15, the FDA has determined it is unable to approve the BLA in its present form, and indicated that there are deficiencies related to the FDA's onsite inspection at Revance's manufacturing facility. Revance plans to request a Type A meeting with the FDA as soon as possible to address the deficiencies raised. No other deficiencies were identified in the CRL.

ShowHide Related Items >><<
RVNC Revance
$22.72 /

+0.24 (+1.07%)

RVNC Revance
$22.72 /

+0.24 (+1.07%)

10/13/21 Mizuho
Revance issues in Form 483 'must be very addressable,' says Mizuho
10/13/21 H.C. Wainwright
Revance price target lowered to $26 from $35 at H.C. Wainwright
10/12/21 William Blair
Revance likely already responded to FDA plant observations, says William Blair
09/15/21 Piper Sandler
Doctor survey favorable for Revance facial injectables, says Piper Sandler
RVNC Revance
$22.72 /

+0.24 (+1.07%)

RVNC Revance
$22.72 /

+0.24 (+1.07%)

Hot Stocks
Femsa CEO Eduardo Padilla to retire, Daniel Rodriguez Cofre to succeed » 17:11
10/15/21
10/15
17:11
10/15/21
17:11
FMX

Femsa

$84.16 /

+0.31 (+0.37%)

Femsa announced that in…

Femsa announced that in accordance with its senior leadership succession planning process, and consistent with previously established timeframes, Eduardo Padilla will retire from his position as Femsa's CEO on January 1, 2022. Accordingly, Femsa's Board of Directors has appointed Daniel Rodriguez Cofre, currently CEO of Femsa Comercio, to become Femsa's CEO as of January 1, 2022. Daniel Rodriguez Cofre joined Femsa in 2015 as Chief Corporate Officer and, since January of 2016, he has been CEO of Femsa Comercio. Prior to Femsa, Daniel occupied several senior finance positions at Shell, and he was CFO and CEO at Cencosud.

ShowHide Related Items >><<
FMX Femsa
$84.16 /

+0.31 (+0.37%)

FMX Femsa
$84.16 /

+0.31 (+0.37%)

08/13/21
Fly Intel: Top five analyst initiations
08/13/21 Goldman Sachs
Femsa initiated with a Buy at Goldman Sachs
08/03/21 Barclays
Femsa price target raised to $90 from $80 at Barclays
08/03/21 Barclays
Femsa price target raised to $90 from $80 at Barclays
FMX Femsa
$84.16 /

+0.31 (+0.37%)

Hot Stocks
Amazon.com supports DOJ's prosecution of four defendant charged with fraud » 17:06
10/15/21
10/15
17:06
10/15/21
17:06
AMZN

Amazon.com

$3,409.08 /

+110.11 (+3.34%)

The United States…

The United States Attorney's Office for the Western District of Michigan charged four individuals in a more than 30 count indictment for their role in defrauding Amazon's textbook rental program. The charges include mail fraud, wire fraud, and making false statements. Amazon's robust anti-fraud systems discovered this scheme and it supported the multi-year investigation. Amazon stated, "Only through close collaboration with law enforcement is the prosecution of fraud like this possible. We are grateful to the United States Attorney's Office for the Western District of Michigan, the Federal Bureau of Investigation, and the U.S. Postal Inspector of Michigan in their thorough pursuit of this case. Fraud undermines the trust of our customers, and jeopardizes the value and selection that entrepreneurs, authors, and publishers provide to millions of customers through our stores. We will continue to pursue all available measures to protect our customers and hold bad actors accountable."

ShowHide Related Items >><<
AMZN Amazon.com
$3,409.08 /

+110.11 (+3.34%)

AMZN Amazon.com
$3,409.08 /

+110.11 (+3.34%)

10/13/21 Baird
Amazon.com weakness would be a buying opportunity, says Baird
10/12/21 JPMorgan
JPMorgan says Alphabet 'clearly the most liked' mega-cap internet stock
10/11/21 Loop Capital
Bed Bath & Beyond price target lowered to $14 from $18 at Loop Capital
10/07/21 Stephens
Comcast-branded Smart TV Launch in U.S. 'likely imminent,' says Stephens
AMZN Amazon.com
$3,409.08 /

+110.11 (+3.34%)

AMZN Amazon.com
$3,409.08 /

+110.11 (+3.34%)

AMZN Amazon.com
$3,409.08 /

+110.11 (+3.34%)

AMZN Amazon.com
$3,409.08 /

+110.11 (+3.34%)

Hot Stocks
General Dynamics awarded $269.49M Navy contract modification » 17:06
10/15/21
10/15
17:06
10/15/21
17:06
GD

General Dynamics

$207.92 /

+2.78 (+1.36%)

General Dynamics was…

General Dynamics was awarded a $269.49M cost-plus-fixed-fee modification to previously awarded contract for lead yard support and development studies and design efforts related to Virginia-class submarines. Work is expected to be completed by October 16. FY21 research, development, test, and evaluation funds in the amount of $13M will be obligated at time of award and will expire at the end of the current fiscal year. This contract was not competitively procured. The statutory authority for this sole source award is in accordance with Defense Federal Acquisition Regulation 6.302-1- only one responsible source and no other supplies or services will satisfy agency requirements. The Naval Sea Systems Command is the contracting activity.

ShowHide Related Items >><<
GD General Dynamics
$207.92 /

+2.78 (+1.36%)

GD General Dynamics
$207.92 /

+2.78 (+1.36%)

09/23/21
Fly Intel: Top five analyst upgrades
09/23/21 Goldman Sachs
General Dynamics upgraded to Neutral from Sell at Goldman Sachs
09/21/21 Morgan Stanley
New AUKUS pact could benefit General Dynamics, Raytheon, says Morgan Stanley
07/29/21 Credit Suisse
General Dynamics price target raised to $198 from $182 at Credit Suisse
GD General Dynamics
$207.92 /

+2.78 (+1.36%)

GD General Dynamics
$207.92 /

+2.78 (+1.36%)

GD General Dynamics
$207.92 /

+2.78 (+1.36%)

Hot Stocks
Hertz intends to apply to list its common stock on Nasdaq » 17:02
10/15/21
10/15
17:02
10/15/21
17:02
HTZZ

Hertz

$25.70 /

-0.979 (-3.67%)

Hertz's common stock…

Hertz's common stock currently trades on the over-the-counter market under the symbol "HTZZ". Hertz intends to apply to list its common stock on the Nasdaq Global Select Market under the symbol "HTZ".

ShowHide Related Items >><<
HTZZ Hertz
$25.70 /

-0.979 (-3.67%)

HTZZ Hertz
$25.70 /

-0.979 (-3.67%)

07/07/21 Deutsche Bank
Hertz price target raised to $18 from $2 at Deutsche Bank
HTZZ Hertz
$25.70 /

-0.979 (-3.67%)

HTZZ Hertz
$25.70 /

-0.979 (-3.67%)

General news
Treasury Market Summary » 17:00
10/15/21
10/15
17:00
10/15/21
17:00
$ECON

Economic Data

/

+

Treasury Market Summary:…

Treasury Market Summary: risk appetite continued to improve on the heels of strong bank earnings and a better than expected retail sales data. Goldman Sachs' knock Q3 performance added to the stellar reports through the week and an upward surprise in sales eased worries over slowing growth. The Dow was over 1% firmer in late action to lead the rally, thanks in large part to Goldman. The S&P 500 was 0.75% higher, and the NASDAQ was up 0.5%. The demand for stocks left bonds out in the cold and yields ballooned higher, paced by the belly as expectations for Fed liftoff around Q3 2022 continue to rise. The 5-year yield was over 7 bps cheaper at 1.122% into the close. The 10-year rose over 6 bps to 1.575%. The 2-year climbed a steep 4 bps to hit 0.40%, with a 4-handle not seen since March 19, 2020. A heavy data slate included the aforementioned retail sales, a slip in the Empire State manufacturing index, slight erosion in consumer sentiment, and rising trade prices.

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

Syndicate
Hertz files to sell common stock for holders, no amount given » 16:59
10/15/21
10/15
16:59
10/15/21
16:59
HTZZ

Hertz

$25.70 /

-0.979 (-3.67%)

The offering is expected…

The offering is expected to be commenced in the fourth quarter, subject to market conditions and completion of any regulatory review. Hertz's common stock currently trades on the over-the-counter market under the symbol "HTZZ". Hertz intends to apply to list its common stock on the Nasdaq Global Select Market under the symbol "HTZ" in connection with the offering. Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, and Morgan Stanley & Co. LLC are acting as lead-bookrunning managers for the proposed offering. Barclays Capital Inc. and Deutsche Bank Securities Inc. are acting as additional bookrunners.

ShowHide Related Items >><<
HTZZ Hertz
$25.70 /

-0.979 (-3.67%)

HTZZ Hertz
$25.70 /

-0.979 (-3.67%)

07/07/21 Deutsche Bank
Hertz price target raised to $18 from $2 at Deutsche Bank
HTZZ Hertz
$25.70 /

-0.979 (-3.67%)

HTZZ Hertz
$25.70 /

-0.979 (-3.67%)

Syndicate
Gritstone files to sell 5M shares of common stock for holders  16:55
10/15/21
10/15
16:55
10/15/21
16:55
GRTS

Gritstone

$9.22 /

-0.16 (-1.71%)

 
ShowHide Related Items >><<
GRTS Gritstone
$9.22 /

-0.16 (-1.71%)

GRTS Gritstone
$9.22 /

-0.16 (-1.71%)

10/14/21 BTIG
Gritstone assumed with a Buy at BTIG
01/21/21 BTIG
Gritstone Oncology price target raised to $35 from $17 at BTIG
01/20/21 H.C. Wainwright
Gritstone Oncology price target raised to $24 from $16 at H.C. Wainwright
01/20/21 Baird
Gritstone Oncology downgraded to Underperform from Outperform at Baird
GRTS Gritstone
$9.22 /

-0.16 (-1.71%)

GRTS Gritstone
$9.22 /

-0.16 (-1.71%)

Syndicate
Solaris Oilfield files $500M mixed securities shelf  16:49
10/15/21
10/15
16:49
10/15/21
16:49
SOI

Solaris Oilfield

$8.22 /

+0.05 (+0.61%)

 
ShowHide Related Items >><<
SOI Solaris Oilfield
$8.22 /

+0.05 (+0.61%)

SOI Solaris Oilfield
$8.22 /

+0.05 (+0.61%)

04/09/21 Cowen
Solaris Oilfield downgraded to Market Perform from Outperform at Cowen
02/25/21 B. Riley
Solaris Oilfield price target raised to $14 from $12.50 at B. Riley Securities
01/25/21 B. Riley
Solaris Oilfield price target raised to $12.50 from $11 at B. Riley Securities
12/15/20 Citi
Solaris Oilfield price target raised to $9.60 from $7 at Citi
SOI Solaris Oilfield
$8.22 /

+0.05 (+0.61%)

Hot Stocks
Medtronic provides update on SPYRAL HTN-ON MED clinical study » 16:46
10/15/21
10/15
16:46
10/15/21
16:46
MDT

Medtronic

$127.65 /

+2.86 (+2.29%)

Medtronic is providing an…

Medtronic is providing an update on its SPYRAL HTN-ON MED clinical study of its Symplicity Renal Denervation System to lower blood pressure in typical hypertensive patients taking up to three anti-hypertensive medications. On September 10, the company announced that it was expecting a prespecified interim data analysis of its ON MED study in October. The company is announcing today that it has received notification from its ON MED study independent data safety monitoring board that it has conducted the prespecified interim data analysis and has recommended that clinical trial enrollment continue as planned, until the full, predefined sample size is reached. A prespecified interim analysis is designed to enable early stoppage of clinical trial enrollment should the results be significantly better than the planned clinical trial design assumptions. The trial was designed to follow 260 randomized patients for 6 months post procedure and is powered to detect a statistically significant and clinically relevant therapeutic benefit at the final analysis. The company estimates that the follow-up of the full cohort of patients will be complete in the second half of calendar year 2022. The statistically significant results from the company's three previous sham-controlled SPYRAL studies, and the data from the company's Global Symplicity Registry of more than 3,000 real-world patients, give the company confidence in its renal denervation program, including ultimate approval of the therapy. These data, in addition to the full clinical cohort, will complete the company's robust premarket application to the U.S. FDA. The company expects renal denervation to become a multi-billion dollar market, with global market revenue now expected to exceed $500M by calendar year 2026 and $2-$3B by calendar year 2030. Of note, this update does not impact the company's fiscal year 2022 revenue and EPS guidance, nor does it affect the company's long-range plan to deliver 5%+ organic revenue growth and 8%+ adjusted EPS growth. Management remains confident in its outlook and its pipeline, including its renal denervation program.

ShowHide Related Items >><<
MDT Medtronic
$127.65 /

+2.86 (+2.29%)

MDT Medtronic
$127.65 /

+2.86 (+2.29%)

09/14/21 Piper Sandler
CMS full repeal proposal of MCIT negative for med tech, says Piper Sandler
08/27/21 Argus
Medtronic price target raised to $165 from $150 at Argus
08/25/21 Truist
Medtronic price target raised to $148 from $138 at Truist
08/25/21 Credit Suisse
Medtronic price target raised to $146 from $137 at Credit Suisse
MDT Medtronic
$127.65 /

+2.86 (+2.29%)

MDT Medtronic
$127.65 /

+2.86 (+2.29%)

MDT Medtronic
$127.65 /

+2.86 (+2.29%)

MDT Medtronic
$127.65 /

+2.86 (+2.29%)

Syndicate
Kore Group files to sell 22.5M shares of common stock for holders  16:37
10/15/21
10/15
16:37
10/15/21
16:37
KORE

Kore Group

$6.82 /

-0.445 (-6.13%)

 
ShowHide Related Items >><<
KORE Kore Group
$6.82 /

-0.445 (-6.13%)

KORE Kore Group
$6.82 /

-0.445 (-6.13%)

10/11/21 Cowen
Kore Group initiated with an Outperform at Cowen
10/01/21 LightShed Partners
Kore Group initiated with a Buy at LightShed Partners
08/16/21 Northland
Cerberus Telecom Acquisition initiated with an Outperform at Northland
Conference/Events
Accuray to hold analyst & investor meeting » 16:36
10/15/21
10/15
16:36
10/15/21
16:36
ARAY

Accuray

$3.94 /

+0.03 (+0.77%)

Analyst & Investor…

Analyst & Investor Meeting being held in conjunction with the ASTRO Annual Meeting on October 25 at 4 pm. Webcast Link

ShowHide Related Items >><<
ARAY Accuray
$3.94 /

+0.03 (+0.77%)

ARAY Accuray
$3.94 /

+0.03 (+0.77%)

01/07/21
Fly Intel: Top five analyst initiations
01/07/21 Northland
Accuray initiated with an Outperform at Northland
ARAY Accuray
$3.94 /

+0.03 (+0.77%)

Syndicate
Murphy Oil files automatic mixed securities shelf  16:35
10/15/21
10/15
16:35
10/15/21
16:35
MUR

Murphy Oil

$28.52 /

-0.16 (-0.56%)

 
ShowHide Related Items >><<
MUR Murphy Oil
$28.52 /

-0.16 (-0.56%)

MUR Murphy Oil
$28.52 /

-0.16 (-0.56%)

10/07/21 Truist
Murphy Oil price target raised to $40 from $37 at Truist
07/15/21 Mizuho
Murphy Oil price target raised to $28 from $24 at Mizuho
07/01/21 Truist
Murphy Oil price target raised to $36 from $24 at Truist
05/17/21 Mizuho
Murphy Oil price target raised to $24 from $21 at Mizuho
MUR Murphy Oil
$28.52 /

-0.16 (-0.56%)

MUR Murphy Oil
$28.52 /

-0.16 (-0.56%)

On The Fly
Short Interest Report: New York Times shorts squeezed by breakout » 16:33
10/15/21
10/15
16:33
10/15/21
16:33
BGFV

Big 5 Sporting

$23.95 /

-0.06 (-0.25%)

, FUV

Arcimoto

$10.33 /

-0.17 (-1.62%)

, LXU

LSB Industries

$9.25 /

-0.315 (-3.29%)

, MSTR

MicroStrategy

$750.46 /

+24.31 (+3.35%)

, PHAS

PhaseBio

$3.98 /

-0.02 (-0.50%)

, BOLT

Bolt Biotherapeutics

$13.52 /

-0.03 (-0.22%)

, NYT

New York Times

$53.15 /

-1.16 (-2.14%)

, SDC

SmileDirectClub

$5.53 /

-0.21 (-3.66%)

Welcome to this week’s…

ShowHide Related Items >><<
SDC SmileDirectClub
$5.53 /

-0.21 (-3.66%)

PHAS PhaseBio
$3.98 /

-0.02 (-0.50%)

NYT New York Times
$53.15 /

-1.16 (-2.14%)

MSTR MicroStrategy
$750.46 /

+24.31 (+3.35%)

LXU LSB Industries
$9.25 /

-0.315 (-3.29%)

FUV Arcimoto
$10.33 /

-0.17 (-1.62%)

BOLT Bolt Biotherapeutics
$13.52 /

-0.03 (-0.22%)

BGFV Big 5 Sporting
$23.95 /

-0.06 (-0.25%)

BGFV Big 5 Sporting
$23.95 /

-0.06 (-0.25%)

08/04/21 Lake Street
Big 5 Sporting price target raised to $31 from $26 at Lake Street
05/05/21 Lake Street
Big 5 Sporting price target raised to $26 from $19 at Lake Street
03/03/21 Lake Street
Big 5 Sporting price target raised to $19 from $16 at Lake Street
01/14/21 Lake Street
Lake Street bumps Big 5 Sporting price target to $16 after Q4 pre-announcement
FUV Arcimoto
$10.33 /

-0.17 (-1.62%)

09/10/21
Fly Intel: Top five analyst initiations
09/10/21 Alliance Global Partners
Arcimoto initiated with a Buy at Alliance Global Partners
04/01/21
Fly Intel: Top five analyst downgrades
04/01/21 H.C. Wainwright
Arcimoto downgraded to Neutral from Buy at H.C. Wainwright
LXU LSB Industries
$9.25 /

-0.315 (-3.29%)

MSTR MicroStrategy
$750.46 /

+24.31 (+3.35%)

08/24/21 Jefferies
MicroStrategy price target raised to $700 from $640 at Jefferies
08/20/21 Citi
Citi places Sell rating on MicroStrategy under review over bitcoin
07/30/21 Canaccord
MicroStrategy price target lowered to $780 from $920 at Canaccord
07/30/21 BTIG
MicroStrategy price target raised to $950 from $850 at BTIG
PHAS PhaseBio
$3.98 /

-0.02 (-0.50%)

10/13/21 Stifel
PhaseBio resumed with a Buy at Stifel
05/14/21 William Blair
PhaseBio remains 'significantly undervalued,' says William Blair
03/16/21 Needham
PhaseBio price target raised to Street high $19 at Needham
BOLT Bolt Biotherapeutics
$13.52 /

-0.03 (-0.22%)

03/02/21
Fly Intel: Top five analyst initiations
03/02/21 SVB Leerink
Bolt Biotherapeutics initiated with an Outperform at SVB Leerink
03/02/21 Morgan Stanley
Bolt Biotherapeutics initiated with an Overweight at Morgan Stanley
03/02/21 Stifel
Bolt Biotherapeutics initiated with a Buy at Stifel
NYT New York Times
$53.15 /

-1.16 (-2.14%)

05/06/21 JPMorgan
New York Times shares may be range-bound near term, says JPMorgan
03/18/21 Guggenheim
Guggenheim upgrades News Corp. to Buy, sees 'significant value' to be unlocked
11/09/20 Evercore ISI
New York Times upgraded to Outperform from In Line at Evercore ISI
10/27/20 JPMorgan
New York Times selloff brings attractive entry point, says JPMorgan
SDC SmileDirectClub
$5.53 /

-0.21 (-3.66%)

09/30/21 Credit Suisse
SmileDirectClub assumed with an Outperform at Credit Suisse
09/20/21 Stifel
Stifel cuts SmileDirectClub to Hold on market share loss, growth uncertainty
09/20/21 Stifel
SmileDirectClub downgraded to Hold from Buy at Stifel
08/13/21
Fly Intel: Top five analyst downgrades
SDC SmileDirectClub
$5.53 /

-0.21 (-3.66%)

PHAS PhaseBio
$3.98 /

-0.02 (-0.50%)

NYT New York Times
$53.15 /

-1.16 (-2.14%)

MSTR MicroStrategy
$750.46 /

+24.31 (+3.35%)

LXU LSB Industries
$9.25 /

-0.315 (-3.29%)

FUV Arcimoto
$10.33 /

-0.17 (-1.62%)

BOLT Bolt Biotherapeutics
$13.52 /

-0.03 (-0.22%)

  • 18
    Mar
  • 05
    Feb
  • 24
    Nov
  • 19
    Nov
SDC SmileDirectClub
$5.53 /

-0.21 (-3.66%)

NYT New York Times
$53.15 /

-1.16 (-2.14%)

MSTR MicroStrategy
$750.46 /

+24.31 (+3.35%)

SDC SmileDirectClub
$5.53 /

-0.21 (-3.66%)

PHAS PhaseBio
$3.98 /

-0.02 (-0.50%)

NYT New York Times
$53.15 /

-1.16 (-2.14%)

MSTR MicroStrategy
$750.46 /

+24.31 (+3.35%)

FUV Arcimoto
$10.33 /

-0.17 (-1.62%)

BGFV Big 5 Sporting
$23.95 /

-0.06 (-0.25%)

SDC SmileDirectClub
$5.53 /

-0.21 (-3.66%)

MSTR MicroStrategy
$750.46 /

+24.31 (+3.35%)

FUV Arcimoto
$10.33 /

-0.17 (-1.62%)

BGFV Big 5 Sporting
$23.95 /

-0.06 (-0.25%)

Hot Stocks
AMC Theatres launches open caption program in 101 U.S. markets » 16:33
10/15/21
10/15
16:33
10/15/21
16:33
AMC

AMC Entertainment

$40.73 /

+0.65 (+1.62%)

AMC Theatres announced…

AMC Theatres announced that as of this week, guests can find select showtimes utilizing an open caption format at 240 AMC locations, in more than 100 U.S. markets. The offering of some open caption showtimes for all new release movies is intended to expand the overall movie-going audience, especially intended for those with hearing difficulties or where English is a second language. Of course, all AMC moviegoers are welcome at open caption showtimes. As of this week, guests at participating AMC locations can find clearly marked open caption showtimes on AMCTheatres.com and the AMC mobile app. The showtimes currently represent a mix of weekend and weekdays, evenings and matinees, and are expected to evolve with movie-going demand and guest feedback. In addition to public showtimes, open captions are now available through AMC's Private Theatre Rentals program at participating locations. While AMC is excited to offer open captioning for those of our guests who desire this format, the vast majority of showtimes at AMC will continue to be offered with closed captioning. Therefore, AMC will continue to have assisted listening devices available at all of its locations nationwide.

ShowHide Related Items >><<
AMC AMC Entertainment
$40.73 /

+0.65 (+1.62%)

AMC AMC Entertainment
$40.73 /

+0.65 (+1.62%)

09/01/21
Fly Intel: Top five analyst downgrades
09/01/21 Macquarie
AMC Entertainment downgraded to Underperform from Neutral at Macquarie
08/30/21 JPMorgan
Movie executives see 10% of screens closing, down from 15%, says JPMorgan
08/24/21 MKM Partners
Slow box office to make AMC Entertainment recovery difficult, says MKM Partners
AMC AMC Entertainment
$40.73 /

+0.65 (+1.62%)

AMC AMC Entertainment
$40.73 /

+0.65 (+1.62%)

AMC AMC Entertainment
$40.73 /

+0.65 (+1.62%)

AMC AMC Entertainment
$40.73 /

+0.65 (+1.62%)

Hot Stocks
Lennar increases share repurchase authorization to up to $1B » 16:30
10/15/21
10/15
16:30
10/15/21
16:30
LEN

Lennar

$97.10 /

-1.25 (-1.27%)

Lennar Corporation…

Lennar Corporation announced that its board of directors increased the authorization for the company to repurchase its own shares from time to time by up to the lesser of $1B in purchase price, or 25M in shares, of the company's outstanding Class A or Class B common stock. The repurchase authorization has no expiration date.

ShowHide Related Items >><<
LEN Lennar
$97.10 /

-1.25 (-1.27%)

LEN Lennar
$97.10 /

-1.25 (-1.27%)

10/14/21 JPMorgan
Lennar price target lowered to $127 from $143 at JPMorgan
09/27/21 Argus
Lennar to continue to benefit from demand for affordable housing, says Argus
09/22/21 Wedbush
Lennar price target raised to $120 from $110 at Wedbush
09/22/21 BTIG
Lennar price target raised to $131 from $127 at BTIG
LEN Lennar
$97.10 /

-1.25 (-1.27%)

LEN Lennar
$97.10 /

-1.25 (-1.27%)

LEN Lennar
$97.10 /

-1.25 (-1.27%)

LEN Lennar
$97.10 /

-1.25 (-1.27%)

Options
Preliminary option volume of 46.5M today » 16:30
10/15/21
10/15
16:30
10/15/21
16:30

Preliminary option volume…

Preliminary option volume of 46.5M today is 24% above recent average. Calls led puts 28.44M to 18.09M.

Syndicate
Evergy files to sell 2.27M shares of common stock for holders  16:25
10/15/21
10/15
16:25
10/15/21
16:25
EVRG

Evergy

$63.44 /

-0.17 (-0.27%)

 
ShowHide Related Items >><<
EVRG Evergy
$63.44 /

-0.17 (-0.27%)

EVRG Evergy
$63.44 /

-0.17 (-0.27%)

09/15/21
Fly Intel: Top five analyst downgrades
09/15/21 BofA
Evergy downgraded to Neutral from Buy at BofA
09/15/21 BofA
Evergy downgraded to Neutral from Buy at BofA
07/07/21 Seaport Global
Seaport Global starts Evergy at Buy, believes 7% EPS growth goal possible
EVRG Evergy
$63.44 /

-0.17 (-0.27%)

EVRG Evergy
$63.44 /

-0.17 (-0.27%)

Options
Closing CBOE SPX and VIX Index summary for October 15th » 16:20
10/15/21
10/15
16:20
10/15/21
16:20
VIX

Volatility Index S&P 500 Options

/

+

The CBOE Volatility Index…

The CBOE Volatility Index (VIX), the SPX option derived measure of implied volatility, fell 0.56 today to close at 16.30, while the underlying SPX index gained 33.11 to close at $4471.37, a 0.75% increase. 697,865 VIX option contracts traded, 1.5635x the typical daily volume for the product. Calls made up 46.5% of the volume.

ShowHide Related Items >><<
VIX Volatility Index S&P 500 Options
/

+

Syndicate
Orphazyme files to sell $75M of ordinary shares  16:18
10/15/21
10/15
16:18
10/15/21
16:18
ORPH

Orphazyme

$4.24 /

+0.04 (+0.95%)

 
ShowHide Related Items >><<
ORPH Orphazyme
$4.24 /

+0.04 (+0.95%)

ORPH Orphazyme
$4.24 /

+0.04 (+0.95%)

06/21/21 Guggenheim
Orphazyme downgraded to Sell after CRL at Guggenheim
06/21/21 Guggenheim
Orphazyme downgraded to Sell from Neutral at Guggenheim
06/18/21 Cowen
Orphazyme downgraded to Market Perform from Outperform at Cowen
03/30/21 BofA
Orphazyme downgraded to Underperform from Neutral at BofA
ORPH Orphazyme
$4.24 /

+0.04 (+0.95%)

ORPH Orphazyme
$4.24 /

+0.04 (+0.95%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.